Lisanti Capital Growth LLC purchased a new position in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 252,215 shares of the company's stock, valued at approximately $2,116,000. Lisanti Capital Growth LLC owned 0.40% of Treace Medical Concepts at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. William Blair Investment Management LLC boosted its position in shares of Treace Medical Concepts by 22.9% during the 4th quarter. William Blair Investment Management LLC now owns 2,938,848 shares of the company's stock worth $21,865,000 after acquiring an additional 546,787 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Treace Medical Concepts by 56.6% during the 4th quarter. JPMorgan Chase & Co. now owns 1,977,219 shares of the company's stock worth $14,711,000 after acquiring an additional 714,984 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Treace Medical Concepts by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 1,062,765 shares of the company's stock worth $7,909,000 after acquiring an additional 22,159 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Treace Medical Concepts by 11.4% during the 4th quarter. Nuveen Asset Management LLC now owns 472,840 shares of the company's stock worth $3,518,000 after acquiring an additional 48,525 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Treace Medical Concepts by 2.3% during the 4th quarter. Northern Trust Corp now owns 468,894 shares of the company's stock worth $3,489,000 after acquiring an additional 10,711 shares in the last quarter. Hedge funds and other institutional investors own 84.08% of the company's stock.
Treace Medical Concepts Stock Up 2.9%
Shares of NASDAQ TMCI opened at $5.75 on Friday. The stock has a market cap of $361.62 million, a PE ratio of -6.76 and a beta of 0.68. The company has a quick ratio of 3.36, a current ratio of 4.50 and a debt-to-equity ratio of 0.51. Treace Medical Concepts, Inc. has a 52-week low of $4.54 and a 52-week high of $10.79. The business has a 50-day moving average price of $6.30 and a 200 day moving average price of $7.66.
Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.06. Treace Medical Concepts had a negative return on equity of 48.69% and a negative net margin of 25.14%. The firm had revenue of $52.57 million during the quarter, compared to analysts' expectations of $52.07 million. During the same period in the prior year, the firm earned ($0.30) EPS. The business's revenue was up 2.9% on a year-over-year basis. Equities research analysts forecast that Treace Medical Concepts, Inc. will post -0.92 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the company. UBS Group lowered their price objective on Treace Medical Concepts from $10.00 to $8.60 and set a "neutral" rating for the company in a research report on Friday, May 9th. Truist Financial lowered their price objective on Treace Medical Concepts from $9.50 to $8.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $10.16.
Read Our Latest Analysis on TMCI
About Treace Medical Concepts
(
Free Report)
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
Further Reading
Want to see what other hedge funds are holding TMCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Treace Medical Concepts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.
While Treace Medical Concepts currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
